Ferguson Wellman Capital Management Inc. Buys 2,270 Shares of Bruker Co. (NASDAQ:BRKR)

Ferguson Wellman Capital Management Inc. increased its holdings in Bruker Co. (NASDAQ:BRKR) by 16.5% in the third quarter, HoldingsChannel.com reports. The fund owned 16,041 shares of the medical research company’s stock after acquiring an additional 2,270 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Bruker were worth $1,108,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Atria Investments Inc purchased a new stake in Bruker in the first quarter worth $1,142,000. Point72 Asset Management L.P. purchased a new position in Bruker during the second quarter valued at $36,472,000. Epoch Investment Partners Inc. lifted its position in Bruker by 15.2% during the first quarter. Epoch Investment Partners Inc. now owns 466,865 shares of the medical research company’s stock valued at $43,857,000 after buying an additional 61,429 shares during the period. Assenagon Asset Management S.A. lifted its position in Bruker by 1,694.4% during the second quarter. Assenagon Asset Management S.A. now owns 202,733 shares of the medical research company’s stock valued at $12,936,000 after buying an additional 191,435 shares during the period. Finally, Federated Hermes Inc. raised its position in shares of Bruker by 5.3% in the 2nd quarter. Federated Hermes Inc. now owns 166,561 shares of the medical research company’s stock worth $10,628,000 after purchasing an additional 8,346 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Stock Down 2.6 %

BRKR stock opened at $54.49 on Friday. Bruker Co. has a twelve month low of $54.33 and a twelve month high of $94.86. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The stock has a market cap of $8.26 billion, a P/E ratio of 26.20, a PEG ratio of 2.68 and a beta of 1.20. The business’s 50-day moving average price is $62.85 and its 200-day moving average price is $65.61.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The company had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. During the same period in the previous year, the firm earned $0.74 earnings per share. The firm’s quarterly revenue was up 16.4% on a year-over-year basis. On average, equities research analysts forecast that Bruker Co. will post 2.4 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wells Fargo & Company lowered their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. TD Cowen reduced their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Citigroup reduced their price objective on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Barclays reduced their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Bruker presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.36.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.